Pathological complete response rate and clinical outcome after neoadjuvant therapy of HER2-low breast cancer: A National Cancer Database Analysis

医学 乳腺癌 内科学 肿瘤科 癌症 新辅助治疗 比例危险模型 病态的 阶段(地层学) 队列 古生物学 生物
作者
Guansheng Zhong,Dajiang Song,Weiyang Lou,Bajin Wei,Yaomin Chen,Hongwu Cui,Jingjing Hu,Huaying Dong,Jie Chen,Zhijun Dai
出处
期刊:Ejso [Elsevier BV]
卷期号:49 (11): 106970-106970 被引量:4
标识
DOI:10.1016/j.ejso.2023.06.022
摘要

Abstract

Background

The interest in breast cancer with low HER2 expression as a distinct subtype is increasing. We aimed to explore the differences between HER2-low and HER2-zero breast cancer in their prognosis and rate of pathological complete response (pCR) after neoadjuvant therapy.

Methods

The National Cancer Database (NCDB) was used to select patients with breast cancer who received neoadjuvant therapy from 2004 to 2017. Logistic regression model was constructed for analysis of pCR. Cox proportional hazards regression model and Kaplan–Meier method were used for survival analysis.

Results

A total of 41500 breast cancer patients were included, among which 14814 (35.7%) had HER2-zero tumors and 26686 (64.3%) had HER2-low. HER2-low tumors were more commonly HR-positive in comparison with HER2-zero (66.3% versus 47.1%, P < 0.001). A lower rate of pCR was observed in HER2-low tumors than in HER2-zero tumors after neoadjuvant therapy in the total cohort (OR = 0.90; 95% CI [0.86–0.95]; P < 0.001) and in the subset of HR-positive (OR = 0.87; 95% CI [0.81–0.94]; P < 0.001). Patients with HER2-low tumors had a significantly superior survival than those with HER2-zero tumors (HR = 0.90; 95% CI [0.86–0.94]; P < 0.001), regardless of the HR status. Additionally, a marginal survival difference was also observed between HER2 IHC1+ and HER2 IHC2+/ISH-negative (HR = 0.91; 95% CI [0.85–0.97]; P = 0.003) cohorts.

Conclusion

HER2-low tumors are a clinically relevant breast cancer subtype that is distinct from HER2-zero tumors. These findings may provide clues to appropriate therapeutic strategies for this subtype in the future.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
2秒前
3秒前
4秒前
立仔发布了新的文献求助10
5秒前
ShengzhangLiu发布了新的文献求助10
5秒前
5秒前
SYLH应助科学采纳,获得10
5秒前
6秒前
Salt发布了新的文献求助10
7秒前
JamesPei应助科研眼镜蛇采纳,获得10
8秒前
听安完成签到,获得积分10
9秒前
77关闭了77文献求助
9秒前
充电宝应助lzr采纳,获得10
10秒前
苗苗发布了新的文献求助10
10秒前
称心凡霜完成签到,获得积分10
15秒前
16秒前
一颗石榴完成签到,获得积分10
16秒前
温离完成签到,获得积分10
17秒前
ZZ发布了新的文献求助10
20秒前
玉昆完成签到 ,获得积分10
21秒前
今后应助吴玉婷采纳,获得30
21秒前
立仔完成签到,获得积分10
22秒前
Zoe_Zhang完成签到 ,获得积分10
23秒前
24秒前
重要的秋尽完成签到,获得积分10
25秒前
111发布了新的文献求助10
25秒前
量子星尘发布了新的文献求助10
25秒前
lzr完成签到,获得积分10
28秒前
28秒前
29秒前
包佳梁完成签到,获得积分10
31秒前
如意含雁关注了科研通微信公众号
31秒前
寒江孤影完成签到,获得积分10
33秒前
ddd123发布了新的文献求助10
33秒前
35秒前
苗苗完成签到,获得积分10
40秒前
Atec发布了新的文献求助10
40秒前
李健的小迷弟应助无名采纳,获得10
41秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975458
求助须知:如何正确求助?哪些是违规求助? 3519866
关于积分的说明 11199996
捐赠科研通 3256213
什么是DOI,文献DOI怎么找? 1798133
邀请新用户注册赠送积分活动 877386
科研通“疑难数据库(出版商)”最低求助积分说明 806305